Leading Pharma acquires growth capital of $40 million

A generic pharmaceutical company Leading Pharma, LLC that manufactures and distributes drug chains, wholesalers declared that it became a successful recipient of $ 40 million of growth capital. The growth capital will advocate pharma research and development R&D investments in growing the company’s varied generic products. Signet Healthcare Partners in addition to Crestline Investors with other investors comprised of Cane Investment Partners and existing Leading Pharma members have spearheaded the transaction.

Ronald Gold, Co-Founder and Chief Executive Officer of Leading Pharma, stated, “This investment allows us to accelerate the development of our robust pipeline to build a more comprehensive product portfolio. We are excited to partner with prudent investors who have experience in the pharmaceutical industry and believe in our business model as well as our ability to develop and market new generic drugs.”

The company operates a 53,000 square foot manufacturing plant committed to oral solid pharmaceuticals. Since the 2014 acquisition of Excellium pharmaceutical, Leading Pharma has outsourced product development work into an integrated generic pharmaceutical company.